1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester is a complex organic molecule with a specific structure. It's important to note that this compound itself isn't typically referred to by that exact name in research. Instead, it's often identified by its role as an **intermediate** in the synthesis of other compounds, specifically **nitroaromatic derivatives**.
Here's a breakdown of the importance of this compound and its derivatives:
* **Synthesis of other compounds:** The structure of 1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester is specifically designed to facilitate reactions that lead to the creation of other useful organic molecules. The nitro group (NO2) on the phenyl ring is a key functional group that can be easily modified, making it a versatile starting point for synthesizing a wide range of compounds.
* **Potential applications:** Nitroaromatic derivatives have found use in various fields, including:
* **Pharmaceuticals:** They are used in the synthesis of pharmaceuticals, including antibiotics, anti-inflammatory drugs, and antitumor agents.
* **Materials science:** They are used in the development of polymers, dyes, and explosives.
* **Agricultural chemistry:** They are used in the development of herbicides and pesticides.
* **Research significance:** The synthesis and characterization of 1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester and its derivatives are crucial for understanding the structure-activity relationships of nitroaromatic compounds. This research helps scientists develop new and improved compounds with specific properties for various applications.
**Key aspects to remember:**
* The exact compound you mentioned is an intermediate, not a final product.
* Its importance lies in its potential to be transformed into other valuable nitroaromatic derivatives.
* Nitroaromatic compounds have a wide range of potential applications in various fields.
Therefore, while the specific name might not be widely used, the compound's role in the synthesis of nitroaromatic derivatives is significant for ongoing research in pharmaceuticals, materials science, and other disciplines.
1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester: structure given in first source
ID Source | ID |
---|---|
PubMed CID | 152434 |
CHEMBL ID | 1098881 |
SCHEMBL ID | 7160123 |
MeSH ID | M0104467 |
Synonym |
---|
EU-0035173 |
OPREA1_010065 , |
CBDIVE_007732 |
OPREA1_510309 |
dimethyl 2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
STK358548 |
AKOS000637843 |
CHEMBL1098881 |
3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)-, dimethyl ester |
2,6-dimethyl-3,5-dicarbomethoxy-4-(4-nitrophenyl)-1,4-dihydropyridine |
1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester |
21829-09-4 |
SCHEMBL7160123 |
AB00076536-01 |
dimethyl 2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate # |
VFQXEYKTWNRSQE-UHFFFAOYSA-N |
dimethyl 1,4-dihydro-2,6-dimethyl-4-(4-nitrophenyl)pyridine-3,5-dicarboxylate |
3,5-dimethyl 2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
DTXSID40176238 |
SR-01000403008-1 |
sr-01000403008 |
2,6-dimethyl-4-(4-nitro-ph)-1,4-2h-pyridine-3,5-dicarboxylic acid dimethyl ester |
Z90350376 |
dimethyl 2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarb oxylate |
DS-19717 |
dimethyl2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
C74081 |
WAA82909 |
PD067229 |
EN300-7378025 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | ID50 | 3,200,000.0000 | 0.0001 | 0.0051 | 0.0100 | AID76980 |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | ID50 | 3,200,000.0000 | 0.0001 | 0.0051 | 0.0100 | AID76980 |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | ID50 | 3,200,000.0000 | 0.0001 | 0.0051 | 0.0100 | AID76980 |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | ID50 | 3,200,000.0000 | 0.0001 | 0.0051 | 0.0100 | AID76980 |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | ID50 | 3,200,000.0000 | 0.0001 | 0.0051 | 0.0100 | AID76980 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID45604 | Negative log antagonist concentration causing 50% displacement of [3H]nifedipine from guinea pig ileal smooth muscle membrane. | 1987 | Journal of medicinal chemistry, Apr, Volume: 30, Issue:4 | Synthesis and calcium channel antagonist activity of dialkyl 4- (dihydropyridinyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylates. |
AID167659 | Compound was tested for ability to relax potassium-contracted rabbit aorta smooth muscle | 1988 | Journal of medicinal chemistry, May, Volume: 31, Issue:5 | Studies directed toward ascertaining the active conformation of 1,4-dihydropyridine calcium entry blockers. |
AID478857 | Selectivity ratio of antagonist activity at rat Cav1.3 to antagonist activity at rabbit Cav1.2 at 1000 nM | 2010 | Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9 | Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. |
AID478847 | Antagonist activity at rat Cav1.3 expressed in HEK293 cells assessed as inhibition of voltage pulse-induced calcium current at 1000 nM by FLIPR calcium 4 assay | 2010 | Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9 | Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. |
AID55897 | Bmax1 from dihydropyridine receptor binding assay in guinea pig myocardial membranes | 1988 | Journal of medicinal chemistry, May, Volume: 31, Issue:5 | Studies directed toward ascertaining the active conformation of 1,4-dihydropyridine calcium entry blockers. |
AID76357 | Effective concentration required to produce mechanical response determined in muscle strips of guinea pig | 1988 | Journal of medicinal chemistry, Nov, Volume: 31, Issue:11 | 1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach. |
AID675414 | Inhibition of L-type voltage-dependent Ca2+ channel at 1 uM | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Ligand-based design, in silico ADME-Tox filtering, synthesis and biological evaluation to discover new soluble 1,4-DHP-based CFTR activators. |
AID45618 | Dissociation constant for inhibition of [3H]nitrendipine binding to guinea pig myocardial membranes | 1988 | Journal of medicinal chemistry, May, Volume: 31, Issue:5 | Studies directed toward ascertaining the active conformation of 1,4-dihydropyridine calcium entry blockers. |
AID675413 | Potentiation of forskolin-induced CFTR deltaF508 mutant expressed in FRT cells co-expressing halide-sensitive YFP-H148Q/I152L by fluorescence quenching assay | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Ligand-based design, in silico ADME-Tox filtering, synthesis and biological evaluation to discover new soluble 1,4-DHP-based CFTR activators. |
AID77341 | Calcium channel antagonistic activity relative to 2,6-Dimethyl-4-(2-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester(=100) | 1982 | Journal of medicinal chemistry, Feb, Volume: 25, Issue:2 | Crystal structures and pharmacological activity of calcium channel antagonists: 2,6-dimethyl-3,5-dicarbomethoxy-4-(unsubstituted, 2-methyl-, 4-methyl-, 3-nitro-, 4-nitro-, and 2,4-dinitrophenyl)-1,4-dihydropyridine. |
AID76980 | Inhibition of muscarinic receptor mediated [Ca2+] dependent contraction of guinea pig ileal longitudinal smooth muscle. | 1987 | Journal of medicinal chemistry, Apr, Volume: 30, Issue:4 | Synthesis and calcium channel antagonist activity of dialkyl 4- (dihydropyridinyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylates. |
AID76978 | Inhibition of muscarinic receptor mediated [Ca2+] dependent contraction of guinea pig ileal longitudinal smooth muscle | 1982 | Journal of medicinal chemistry, Feb, Volume: 25, Issue:2 | Crystal structures and pharmacological activity of calcium channel antagonists: 2,6-dimethyl-3,5-dicarbomethoxy-4-(unsubstituted, 2-methyl-, 4-methyl-, 3-nitro-, 4-nitro-, and 2,4-dinitrophenyl)-1,4-dihydropyridine. |
AID478852 | Antagonist activity at rabbit Cav1.2 expressed in HEK293 cells assessed as inhibition of voltage pulse-induced calcium current at 1000 nM by FLIPR calcium 4 assay | 2010 | Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9 | Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. |
AID76358 | Compound was tested for its antagonist activity against calcium channel | 1988 | Journal of medicinal chemistry, Nov, Volume: 31, Issue:11 | 1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (66.67) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |